Can the EndoPAT™ results predict cardiovascular events?
Yes, in the landmark recent publication by Rubinshtein et al. (*) a joined cohort (from the Mayo clinic and TUFTS) of 270 outpatients were followed up for several years and the incremental value of the EndoPAT index to the Framingham Risk Score (FRS) was assessed. Major Adverse Cardiovascular Events (MACE) that are cardiac death, myocardial infarction, revascularization or cardiac hospitalization, were recorded over an average follow-up period of 5.8 years. The rate of MACE in patients who tested positive for endothelial dysfunction was 39% vs. normal endothelial function 25% (p=0.024). The study showed that patients at low FRS risk but with Endothelial Dysfunction were at a higher actual risk of future CV events than patients with high FRS but normal Endothelial Function. Furthermore, Endothelial Dysfunction was found to be an independent risk factor for future MACE on multivariate analysis (p=0.002). * Rubinshtein R, Kuvin JT, Soffler M, Lennon RJ, Nelson RE, Pumper GM, Lerman LO, Le
